Adverum Biotechnologies Announces Positive 52-Week LUNA and
- 52-week LUNA data combined with follow-up from OPTIC at 4 years continue to support long-term potential best-in-class product profile...
Adverum
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
- Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18th at 7:30 a.m....
